CORRESP Filing
ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895)
Date: March 6, 2026 · CIK: 0001281895 · Accession: 0001140361-26-008290
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293925
Letter
Re: Acceleration Request for Rocket Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-293925)
March 6, 2026
VIA EDGAR
U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attn: Alan Campbell
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Rocket Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on March 10, 2026 or as soon thereafter as is practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff.
It would be appreciated if, as soon as the Registration Statement is declared effective, you would so inform Sean Jones of K&L Gates LLP, our counsel, at (704) 331-7406. We appreciate your assistance in this matter.
Very truly yours,
Rocket Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm March 6, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: Acceleration Request for Rocket Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-293925) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Rocket Pharmaceuticals, Inc. (the “Company”) hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on March 10, 2026 or as soon thereafter as is practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff. It would be appreciated if, as soon as the Registration Statement is declared effective, you would so inform Sean Jones of K&L Gates LLP, our counsel, at (704) 331-7406. We appreciate your assistance in this matter. Very truly yours, Rocket Pharmaceuticals, Inc. By: /s/ Martin Wilson Name: Martin Wilson Title: General Counsel and Chief Corporate Officer